组织蛋白たんぱく酶K

组织蛋白たんぱく酶K
已やめ知的ちてき結構けっこう
PDB	直系ちょっけい同どう源みなもと搜索そうさく: PDBe RCSB
PDBID列れつ表ひょう
	1MEM、3KWB、3KX1、4X6J、1AYW、3KW9、1YT7、1AUえーゆー2、4X6H、1Q6K、1YK7、1ATK、3C9E、1AYV、1BGO、4N8W、7PCK、4DMX、4X6I、1NL6、1TU6、3O0U、1AUえーゆー4、3OVZ、3KWZ、2ATO、3O1G、1AUえーゆー0、1BY8、1SNK、2AUZ、4DMY、4N79、1AYU、1U9X、1YK8、1AUえーゆー3、1U9V、2BDL、1VSN、1U9W、2AUX、2R6N、3H7D、1NLJ、5J94、4YVA、4YV8
識別しきべつ號ごう
别名	CTSK；, CTS02, CTSO, CTSO1, CTSO2, PKND, PYCD, cathepsin K
外部がいぶID	OMIM：601105 MGI：107823 HomoloGene：68053 GeneCards：CTSK
相關そうかん疾病しっぺい
	pycnodysostosis
為ため以下いか藥物やくぶつ的てき標しるべ靶
	odanacatib、odanacatib、balicatib
基もと因いん位置いち（人ひと类）
染色せんしょく体たい	1號ごう染色せんしょく體たい
终止	150,809,577 bp
基もと因いん位置いち（小しょう鼠ねずみ）
染色せんしょく体たい	小しょう鼠ねずみ3号ごう染色せんしょく体たい
终止	95,416,673 bp
RNA表ひょう达模も式しき
	查阅更さら多た表ひょう达数据すえ
基もと因いん本體ほんたい
分子ぶんし功こう能のう	• fibronectin binding; • 半はん胱氨酸さん型がた肽酶活性かっせい; • collagen binding; • 肽酶活性かっせい; • 血ち浆蛋白しろ结合; • cysteine-type endopeptidase activity; • 水みず解かい酶活性せい; • proteoglycan binding; • serine-type endopeptidase activity;
細胞さいぼう組ぐみ分ぶん	• 細胞さいぼう質しつ; • 細胞さいぼう外がい區域くいき; • endolysosome lumen; • 溶酶体たい; • 細胞さいぼう外がい空間くうかん; • 核かく质; • 細胞さいぼう內膜結合けつごう細胞さいぼう器き; • lysosomal lumen;
生物せいぶつ學がく過程かてい	• 膜まく内成うちなり骨こつ; • positive regulation of protein targeting to mitochondrion; • extracellular matrix disassembly; • 骨ほね质吸收きゅうしゅう; • 蛋白たんぱく酶解; • toll-like receptor signaling pathway; • regulation of autophagy of mitochondrion; • collagen catabolic process; • proteolysis involved in cellular protein catabolic process; • regulation of keratinocyte differentiation;
	Sources:Amigo / QuickGO
直系ちょっけい同どう源みなもと
	1513
	13038
	ENSG00000143387
	ENSMUSG00000028111
	P43235
	P55097
	NM_000396
	NM_007802
	NP_000387
	NP_031828
	維基數すう據よりどころ
檢視けんし/編輯へんしゅう人類じんるい	檢視けんし/編輯へんしゅう小しょう鼠ねずみ

组织蛋白たんぱく酶K（英えい语：Cathepsin K），是ぜ一いち种在人体じんたい中ちゅう由ゆかりCTSK基もと因いん编码的てき酶。^[7]^[8]

功こう能のう

该基因いん编码的てき蛋白たんぱく质是半はん胱氨酸さん组织蛋白たんぱく酶，一种参与骨重塑和再吸收的溶酶体たい半はん胱氨酸さん蛋白たんぱく酶。这种蛋白たんぱく质是肽酶C1蛋白たんぱく质家族かぞく的てき成なり员，主要しゅよう在ざい破やぶ骨ほね细胞中表なかおもて达。

组织蛋白たんぱく酶K是ぜ一いち种蛋白たんぱく酶，其特征せい在ざい于其对激げき肽的てき高度こうど特とく异性，与あずか骨ほね吸收きゅうしゅう有ゆう关。该酶分解ぶんかい代だい谢弹性蛋白たんぱく、胶原蛋白たんぱく和わ明あかり胶的てき能力のうりょく使し其能够分解ぶんかい骨骼こっかく和わ软骨。这种分解ぶんかい代だい谢活动也是ぜ肺はい弹性丧失和わ肺はい气肿反はん冲的部分ぶぶん原因げんいん。组织蛋白たんぱく酶K抑制よくせい剂在ざい骨ほね质疏松まつ症しょう的てき治ち疗中显示出で巨大きょだい的てき潜せん力りょく。在ざい被ひ称しょう为受控ひかえ组织蛋白たんぱく酶同类相食しょく的てき过程中ちゅう，组织蛋白たんぱく酶K被ひ组织蛋白たんぱく酶S降くだ解かい。

组织蛋白たんぱく酶K的てき表ひょう达受到组织损伤后きさき释放的てき炎ほのお性せい细胞因子いんし的てき刺激しげき。

临床意い义

组织蛋白たんぱく酶K在ざい很大一いち部分ぶぶん人じん类乳癌にゅうがん中表なかおもて达，它可能かのう有ゆう助じょ于肿瘤こぶ侵おかせ袭性。^[9]该基因いん的てき突变是ぜ致密性せい成なり骨こつ不全ふぜん症しょう的てき原因げんいん，这是一いち种以骨ほね质硬化か和かず身み材ざい矮小わいしょう为特征せい的てき常つね染色せんしょく体たい隐性遗传病びょう。^[10]组织蛋白たんぱく酶K也被发现在ざい胶质母はは细胞瘤こぶ中ちゅう过度表ひょう达。^[11]

组织蛋白たんぱく酶K的てき表ひょう达是某ぼう些癌症しょう的てき特とく征せい，而其他た癌がん症しょう则没有ゆう。^[12]组织蛋白たんぱく酶K抗体こうたい已上いじょう市し销售，用よう于研究けんきゅう该酶在ざい各かく种细胞中的てき表ひょう达。^[13]^[14]^[15]

默だま克かつ公司こうし在ざい骨ほね质疏松まつ症しょう的てきIII期き临床试验中ちゅう使用しよう了りょう一种组织蛋白酶K抑制よくせい剂，奥おく达那替がえ尼あま。2016年ねん9月がつ，默だま克かつ公司こうし在自あらじ行ゆき评估不良ふりょう事件じけん后きさき宣布せんぷ停止ていし开发奥おく达那替がえ尼あま，独立どくりつ评估显示中ちゅう风风险增加ぞうか。^[16]^[17]其他组织蛋白たんぱく酶K抑制よくせい剂处于不同ふどう的てき发展阶段。^[18]^[19]截至2017年ねん10月がつ，Medivir公司こうし有ゆう一种组织蛋白酶K抑制よくせい剂MIV-711（L-006235^[20]^[21]^[22]），在ざいIIa期き临床试验中ちゅう，作さく为一种改善かいぜん骨こつ关节炎えん的てき药物。

参考さんこう文献ぶんけん

^ 與あずか组织蛋白たんぱく酶K相關そうかん的てき疾病しっぺい；在ざい維基數すう據よりどころ上じょう查看/編輯へんしゅう參考さんこう.
^ 對たいCathepsin K起おこり作用さよう的てき藥物やくぶつ；在ざい維基數すう據よりどころ上じょう查看/編輯へんしゅう參考さんこう.
^ ^3.0 ^3.1 ^3.2 GRCh38: Ensembl release 89: ENSG00000143387 - Ensembl, May 2017
^ ^4.0 ^4.1 ^4.2 GRCm38: Ensembl release 89: ENSMUSG00000028111 - Ensembl, May 2017
^ Human PubMed Reference:. National Center for Biotechnology Information, U.S. National Library of Medicine.
^ Mouse PubMed Reference:. National Center for Biotechnology Information, U.S. National Library of Medicine.
^ Entrez Gene: CTSK cathepsin K.
^ Inaoka T, Bilbe G, Ishibashi O, Tezuka K, Kumegawa M, Kokubo T. Molecular cloning of human cDNA for cathepsin K: novel cysteine proteinase predominantly expressed in bone. Biochemical and Biophysical Research Communications. January 1995, 206 (1): 89–96. PMID 7818555. doi:10.1006/bbrc.1995.1013.
^ Duong LT, Wesolowski GA, Leung P, Oballa R, Pickarski M. Efficacy of a Cathepsin K Inhibitor in a Preclinical Model for Prevention and Treatment of Breast Cancer Bone Metastasis. Molecular Cancer Therapeutics. 23 September 2014, 13 (12): 2898–909 [2 October 2016]. PMID 25249554. doi:10.1158/1535-7163.MCT-14-0253 . （原始げんし内容ないよう存そん档于2019-08-24）.
^ CTSK cathepsin K [ Homo sapiens (human) ]. NCBI Gene. National Center for Biotechnology Information, U.S. National Library of Medicine. 4 September 2016 [2 October 2016]. （原始げんし内容ないよう存そん档于2022-10-31）.
^ Verbovšek U, Motaln H, Rotter A, Atai NA, Gruden K, Van Noorden CJ, Lah TT. Expression Analysis of All Protease Genes Reveals Cathepsin K to Be Overexpressed in Glioblastoma. PLOS ONE. 30 October 2014, 9 (10): e111819. Bibcode:2014PLoSO...9k1819V. PMC 4214761 . PMID 25356585. doi:10.1371/journal.pone.0111819 .
^ Argani, Pedram; et al. A Broad Survey of Cathepsin K Immunoreactivity in Human Neoplasms. American Journal of Clinical Pathology. 1 February 2013, 139 (2): 151–159. PMC 3957187 . PMID 23355199. doi:10.1309/AJCPDTRTO2Z4UEXD.
^ Cathepsin K Antibodies. Novus Biologicals online catalog. Novus Biologicals, LLC. 2016 [2 October 2016]. （原始げんし内容ないよう存そん档于2022-10-31）.
^ Anti-Cathepsin K antibody (ab19027). Abcam plc online catalog. Abcam plc. 2016 [2 October 2016]. （原始げんし内容ないよう存そん档于2022-10-31）.
^ Anti-Cathepsin K Antibody (A5871). Antibodies.com online catalog. Antibodies.com Ltd. 2018 [16 January 2018]. （原始げんし内容ないよう存そん档于2018-01-17）.
^ Brömme, Dieter; Lecaille, Fabien. Cathepsin K inhibitors for osteoporosis and potential off-target effects. Expert Opinion on Investigational Drugs. 24 April 2009, 18 (5): 585–600. PMC 3110777 . PMID 19388876. doi:10.1517/13543780902832661.
^ Merck Provides Update on Odanacatib Development Program. Merck Sharp & Dohme Corp. 2 September 2016 [1 October 2016]. （原始げんし内容ないよう存そん档于2016-11-09）.
^ Asagiri M, Hirai T, Kunigami T, Kamano S, Gober HJ, Okamoto K, Nishikawa K, Latz E, Golenbock DT, Aoki K, Ohya K, Imai Y, Morishita Y, Miyazono K, Kato S, Saftig P, Takayanagi H,. (2008). Cathepsin K-dependent toll-like receptor 9 signaling revealed in experimental arthritis. Science, 319(5863), 624-627.
^ Hussein, H., Ishihara, A., Menendez, M., & Bertone, A. (2014). Pharmacokinetics and bone resorption evaluation of a novel Cathepsin K inhibitor (VEL‐0230) in healthy adult horses. Journal of veterinary pharmacology and therapeutics.
^ MIV-711 for the treatment of ostheoarthritis. www.medivir.se. [2017-10-06]. （原始げんし内容ないよう存そん档于6 October 2017）（英えい语）.
^ Burston JJ, Xu L, Mapp PI, Grabowska U, Tunblad K, Lindström E, Chapman V. The Cathepsin K Inhibitor L-006235 Demonstrates Both Disease Modification and Attenuation of Pain Behaviour in the in the Mia Model of Osteoarthritis (PDF). www.medivir.se. April 2016 [6 October 2017]. （原始げんし内容ないよう (PDF)存そん档于6 October 2017）.
^ Data monitoring committee gives "Go Ahead" in the MIV-711 osteoarthritis extension study (PDF). mb.cision.com. 14 September 2017 [2022-10-31]. （原始げんし内容ないよう存そん档 (PDF)于2022-08-21）.

阅读

Motyckova G, Fisher DE. Pycnodysostosis: role and regulation of cathepsin K in osteoclast function and human disease.. Current Molecular Medicine. 2003, 2 (5): 407–21. PMID 12125807. doi:10.2174/1566524023362401.
Troen BR. The regulation of cathepsin K gene expression.. Annals of the New York Academy of Sciences. 2006, 1068 (1): 165–72. Bibcode:2006NYASA1068..165T. PMID 16831915. S2CID 8117602. doi:10.1196/annals.1346.018.
Del Nery E, Chagas JR, Juliano MA, et al. Evaluation of the extent of the binding site in human tissue kallikrein by synthetic substrates with sequences of human kininogen fragments.. The Biochemical Journal. 1996, 312 (1): 233–8. PMC 1136249 . PMID 7492318. doi:10.1042/bj3120233.
Brömme D, Okamoto K. Human cathepsin O2, a novel cysteine protease highly expressed in osteoclastomas and ovary molecular cloning, sequencing and tissue distribution.. Biological Chemistry Hoppe-Seyler. 1995, 376 (6): 379–84. PMID 7576232. doi:10.1515/bchm3.1995.376.6.379.
Gelb BD, Edelson JG, Desnick RJ. Linkage of pycnodysostosis to chromosome 1q21 by homozygosity mapping.. Nature Genetics. 1995, 10 (2): 235–7. PMID 7663521. S2CID 24297764. doi:10.1038/ng0695-235.
Polymeropoulos MH, Ortiz De Luna RI, Ide SE, et al. The gene for pycnodysostosis maps to human chromosome 1cen-q21.. Nature Genetics. 1995, 10 (2): 238–9 [2022-10-31]. PMID 7663522. S2CID 11723845. doi:10.1038/ng0695-238. （原始げんし内容ないよう存そん档于2022-10-31）.
Shi GP, Chapman HA, Bhairi SM, et al. Molecular cloning of human cathepsin O, a novel endoproteinase and homologue of rabbit OC2. (PDF). FEBS Letters. 1995, 357 (2): 129–34. PMID 7805878. S2CID 28099876. doi:10.1016/0014-5793(94)01349-6 .
Inaoka T, Bilbe G, Ishibashi O, et al. Molecular cloning of human cDNA for cathepsin K: novel cysteine proteinase predominantly expressed in bone.. Biochemical and Biophysical Research Communications. 1995, 206 (1): 89–96. PMID 7818555. doi:10.1006/bbrc.1995.1013.
Velasco G, Ferrando AA, Puente XS, et al. Human cathepsin O. Molecular cloning from a breast carcinoma, production of the active enzyme in Escherichia coli, and expression analysis in human tissues.. The Journal of Biological Chemistry. 1994, 269 (43): 27136–42. PMID 7929457. doi:10.1016/S0021-9258(18)47135-9 .
Li YP, Alexander M, Wucherpfennig AL, et al. Cloning and complete coding sequence of a novel human cathepsin expressed in giant cells of osteoclastomas.. Journal of Bone and Mineral Research. 1996, 10 (8): 1197–202. PMID 8585423. S2CID 41832979. doi:10.1002/jbmr.5650100809.
Bossard MJ, Tomaszek TA, Thompson SK, et al. Proteolytic activity of human osteoclast cathepsin K. Expression, purification, activation, and substrate identification.. Journal of Biological Chemistry. 1996, 271 (21): 12517–24. PMID 8647860. doi:10.1074/jbc.271.21.12517 .
Gelb BD, Shi GP, Chapman HA, Desnick RJ. Pycnodysostosis, a lysosomal disease caused by cathepsin K deficiency.. Science. 1996, 273 (5279): 1236–8. Bibcode:1996Sci...273.1236G. PMID 8703060. S2CID 7188076. doi:10.1126/science.273.5279.1236.
Johnson MR, Polymeropoulos MH, Vos HL, et al. A nonsense mutation in the cathepsin K gene observed in a family with pycnodysostosis.. Genome Research. 1997, 6 (11): 1050–5. PMID 8938428. doi:10.1101/gr.6.11.1050 .
Littlewood-Evans A, Kokubo T, Ishibashi O, et al. Localization of cathepsin K in human osteoclasts by in situ hybridization and immunohistochemistry.. Bone. 1997, 20 (2): 81–6. PMID 9028530. doi:10.1016/S8756-3282(96)00351-1.
McGrath ME, Klaus JL, Barnes MG, Brömme D. Crystal structure of human cathepsin K complexed with a potent inhibitor.. Nature Structural Biology. 1997, 4 (2): 105–9. PMID 9033587. S2CID 22175354. doi:10.1038/nsb0297-105.
Rood JA, Van Horn S, Drake FH, et al. Genomic organization and chromosome localization of the human cathepsin K gene (CTSK).. Genomics. 1997, 41 (2): 169–76. PMID 9143491. doi:10.1006/geno.1997.4614.
Gelb BD, Shi GP, Heller M, et al. Structure and chromosomal assignment of the human cathepsin K gene.. Genomics. 1997, 41 (2): 258–62. PMID 9143502. doi:10.1006/geno.1997.4631.
Gomes RA, Juliano L, Chagas JR, Hial V. Characterization of kininogenase activity of an acidic proteinase isolated from human kidney.. Canadian Journal of Physiology and Pharmacology. 1997, 75 (6): 757–61. PMID 9276160. doi:10.1139/cjpp-75-6-757.
Thompson SK, Halbert SM, Bossard MJ, et al. Design of potent and selective human cathepsin K inhibitors that span the active site.. Proceedings of the National Academy of Sciences. 1998, 94 (26): 14249–54. PMC 24926 . PMID 9405598. doi:10.1073/pnas.94.26.14249 .
Gelb BD, Willner JP, Dunn TM, et al. Paternal uniparental disomy for chromosome 1 revealed by molecular analysis of a patient with pycnodysostosis.. The American Journal of Human Genetics. 1998, 62 (4): 848–54. PMC 1377035 . PMID 9529353. doi:10.1086/301795.

图集

Osteoclast

外部がいぶ链接

The MEROPS online database for peptidases and their inhibitors: C01.036
醫學いがく主題しゅだい詞し表ひょう（MeSH）：Cathepsin+K

[1] 與あずか组织蛋白たんぱく酶K相關そうかん的てき疾病しっぺい；在ざい維基數すう據よりどころ上じょう查看/編輯へんしゅう參考さんこう.

[2] 對たいCathepsin K起おこり作用さよう的てき藥物やくぶつ；在ざい維基數すう據よりどころ上じょう查看/編輯へんしゅう參考さんこう.

[refGRCh38Ensembl-3] 3.0 ^3.1 ^3.2 GRCh38: Ensembl release 89: ENSG00000143387 - Ensembl, May 2017

[refGRCm38Ensembl-4] 4.0 ^4.1 ^4.2 GRCm38: Ensembl release 89: ENSMUSG00000028111 - Ensembl, May 2017

[5] Human PubMed Reference:. National Center for Biotechnology Information, U.S. National Library of Medicine.

[6] Mouse PubMed Reference:. National Center for Biotechnology Information, U.S. National Library of Medicine.

[entrez-7] Entrez Gene: CTSK cathepsin K.

[pmid7818555-8] Inaoka T, Bilbe G, Ishibashi O, Tezuka K, Kumegawa M, Kokubo T. Molecular cloning of human cDNA for cathepsin K: novel cysteine proteinase predominantly expressed in bone. Biochemical and Biophysical Research Communications. January 1995, 206 (1): 89–96. PMID 7818555. doi:10.1006/bbrc.1995.1013.

[Duong_2014-9] Duong LT, Wesolowski GA, Leung P, Oballa R, Pickarski M. Efficacy of a Cathepsin K Inhibitor in a Preclinical Model for Prevention and Treatment of Breast Cancer Bone Metastasis. Molecular Cancer Therapeutics. 23 September 2014, 13 (12): 2898–909 [2 October 2016]. PMID 25249554. doi:10.1158/1535-7163.MCT-14-0253 . （原始げんし内容ないよう存そん档于2019-08-24）.

[NCBI_Gene_Card_cathepsin_K-10] CTSK cathepsin K [ Homo sapiens (human) ]. NCBI Gene. National Center for Biotechnology Information, U.S. National Library of Medicine. 4 September 2016 [2 October 2016]. （原始げんし内容ないよう存そん档于2022-10-31）.

[van_Noorden_2014-11] Verbovšek U, Motaln H, Rotter A, Atai NA, Gruden K, Van Noorden CJ, Lah TT. Expression Analysis of All Protease Genes Reveals Cathepsin K to Be Overexpressed in Glioblastoma. PLOS ONE. 30 October 2014, 9 (10): e111819. Bibcode:2014PLoSO...9k1819V. PMC 4214761 . PMID 25356585. doi:10.1371/journal.pone.0111819 .

[Argani_2013-12] Argani, Pedram; et al. A Broad Survey of Cathepsin K Immunoreactivity in Human Neoplasms. American Journal of Clinical Pathology. 1 February 2013, 139 (2): 151–159. PMC 3957187 . PMID 23355199. doi:10.1309/AJCPDTRTO2Z4UEXD.

[NovusBiologicals-13] Cathepsin K Antibodies. Novus Biologicals online catalog. Novus Biologicals, LLC. 2016 [2 October 2016]. （原始げんし内容ないよう存そん档于2022-10-31）.

[Abcam_Catalog-14] Anti-Cathepsin K antibody (ab19027). Abcam plc online catalog. Abcam plc. 2016 [2 October 2016]. （原始げんし内容ないよう存そん档于2022-10-31）.

[Antibodies.com-15] Anti-Cathepsin K Antibody (A5871). Antibodies.com online catalog. Antibodies.com Ltd. 2018 [16 January 2018]. （原始げんし内容ないよう存そん档于2018-01-17）.

[Bromme2009-16] Brömme, Dieter; Lecaille, Fabien. Cathepsin K inhibitors for osteoporosis and potential off-target effects. Expert Opinion on Investigational Drugs. 24 April 2009, 18 (5): 585–600. PMC 3110777 . PMID 19388876. doi:10.1517/13543780902832661.

[MerckFinancial-17] Merck Provides Update on Odanacatib Development Program. Merck Sharp & Dohme Corp. 2 September 2016 [1 October 2016]. （原始げんし内容ないよう存そん档于2016-11-09）.

[18] Asagiri M, Hirai T, Kunigami T, Kamano S, Gober HJ, Okamoto K, Nishikawa K, Latz E, Golenbock DT, Aoki K, Ohya K, Imai Y, Morishita Y, Miyazono K, Kato S, Saftig P, Takayanagi H,. (2008). Cathepsin K-dependent toll-like receptor 9 signaling revealed in experimental arthritis. Science, 319(5863), 624-627.

[19] Hussein, H., Ishihara, A., Menendez, M., & Bertone, A. (2014). Pharmacokinetics and bone resorption evaluation of a novel Cathepsin K inhibitor (VEL‐0230) in healthy adult horses. Journal of veterinary pharmacology and therapeutics.

[20] MIV-711 for the treatment of ostheoarthritis. www.medivir.se. [2017-10-06]. （原始げんし内容ないよう存そん档于6 October 2017）（英えい语）.

[21] Burston JJ, Xu L, Mapp PI, Grabowska U, Tunblad K, Lindström E, Chapman V. The Cathepsin K Inhibitor L-006235 Demonstrates Both Disease Modification and Attenuation of Pain Behaviour in the in the Mia Model of Osteoarthritis (PDF). www.medivir.se. April 2016 [6 October 2017]. （原始げんし内容ないよう (PDF)存そん档于6 October 2017）.

[22] Data monitoring committee gives "Go Ahead" in the MIV-711 osteoarthritis extension study (PDF). mb.cision.com. 14 September 2017 [2022-10-31]. （原始げんし内容ないよう存そん档 (PDF)于2022-08-21）.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

[9]

[10]

[11]

[12]

[13]

[14]

[15]

[16]

[17]

[18]

[19]

[20]

[21]

[22]

查论编蛋白たんぱく酶类：半はん胱氨酸さん蛋白たんぱく酶类（EC 3.4.22)
胱天蛋白たんぱく酶	胱天蛋白たんぱく酶1 胱天蛋白たんぱく酶2 胱天蛋白たんぱく酶3 胱天蛋白たんぱく酶4 胱天蛋白たんぱく酶5 胱天蛋白たんぱく酶6 胱天蛋白たんぱく酶7 胱天蛋白たんぱく酶8 胱天蛋白たんぱく酶9 胱天蛋白たんぱく酶10 胱天蛋白たんぱく酶11 胱天蛋白たんぱく酶12 胱天蛋白たんぱく酶13 胱天蛋白たんぱく酶14
来き自じ果はて实	木瓜ぼけ蛋白たんぱく酶无花果はて蛋白たんぱく酶（英えい语：Ficain）鳳おおとり梨なし蛋白たんぱく酶猕猴桃もも蛋白たんぱく酶
钙蛋白しろ酶	CAPN1 CAPN2 CAPN3 CAPN5 CAPN6 CAPN7 CAPN8 CAPN9 CAPN10 CAPN11 CAPN12 CAPN13 CAPN14 CAPNS1 CAPNS2
组织蛋白たんぱく酶	B C F H K L1/L2 O S T W Z
其它	梭菌蛋白たんぱく酶癌がん性せい促凝物ぶつ质分ぶん离酶（英えい语：Separase） Autophagin Cruzipain 3C样蛋白しろ酶
EC 1.1/2/3/4/5/6/7/8/9/10/11/12/13/14/15/16/17/18/19/20/21/22 · 2.1/2/3/4/5/6/7(2.7.10/11-12)/8/9 · 3.1/2/3/4(3.4.21/22/23/24)/5/6/7/8/9/10/11/12/13 · 4.1/2/3/4/5/6 · 5.1/2/3/4/5/99 · 6.1-3（英えい语：Template:Ligases CO CS and CN）/4/5-6

查论编酶
活性かっせい	活性かっせい位い点てん结合位い点てん催化三さん联体负氧离子洞ほら酶催化か混こん杂（英えい语：Enzyme promiscuity）催化最さい适酶（英えい语：Catalytically perfect enzyme）辅因子いんし辅酶酶促反はん应
调节	别构调节协同性せい（英えい语：Cooperativity）酶抑制よくせい剂酶激活かつ剂
分ぶん类	EC編へん號ごう蛋白たんぱく质超家族かぞく蛋白たんぱく质家族かぞく酶列表ひょう
动力学がく	酶动力学りきがく伊い迪すすむ-霍夫斯蒂图（英えい语：Eadie–Hofstee diagram）哈尼斯-伍ご尔夫图（英えい语：Hanes–Woolf plot）双そう倒たおせ数すう图米よね氏し动力学がく
类型	EC1 氧化還かえ原げん酶（列れつ表ひょう（英えい语：List of EC numbers (EC 1)）） EC2 轉移てんい酶（列れつ表ひょう（英えい语：List of EC numbers (EC 2)）） EC3 水みず解かい酶（列れつ表ひょう（英えい语：List of EC numbers (EC 3)）） EC4 裂きれ合あい酶（列れつ表ひょう（英えい语：List of EC numbers (EC 4)）） EC5 異い構酶（列れつ表ひょう（英えい语：List of EC numbers (EC 5)）） EC6 連接れんせつ酶（列れつ表ひょう（英えい语：List of EC numbers (EC 6)）） EC7 移うつり位い酶（英えい语：Translocase）（列れつ表ひょう（英えい语：List of EC numbers (EC 7)））